The estimated Net Worth of Daniel D Burgess is at least $208 mil dollars as of 2 August 2022. Mr. Burgess owns over 11,341 units of Cidara Therapeutics Inc stock worth over $120,662 and over the last 9 years he sold CDTX stock worth over $3,505. In addition, he makes $84,159 as Independent Chairman of the Board at Cidara Therapeutics Inc.
Sign up
Mr. Burgess CDTX stock SEC Form 4 insiders trading
Daniel has made over 4 trades of the Cidara Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 11,341 units of CDTX stock worth $2,155 on 2 August 2022.
The largest trade he's ever made was buying 36,000 units of Cidara Therapeutics Inc stock on 31 July 2018 worth over $99,000. On average, Daniel trades about 1,775 units every 92 days since 2015. As of 2 August 2022 he still owns at least 10,384 units of Cidara Therapeutics Inc stock.
You can see the complete history of Mr. Burgess stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Daniel Burgess biography
Daniel D. Burgess serves as Independent Chairman of the Board of the Company. Since June 2014, Mr. Burgess has been a venture partner at SV Health Investors, an investment fund. In addition, Mr. Burgess currently serves as the Acting President and Chief Executive Officer and a director of Therini Bio, Inc, a private vascular biology company. From June 2011 until its acquisition by The Medicines Company in December 2013, he served as the President and Chief Executive Officer of Rempex Pharmaceuticals, Inc., a private biopharmaceutical company, and from December 2013 until June 2014, he continued as the head of the acquired company within The Medicines Company. Prior to joining Rempex, Mr. Burgess held positions at Mpex Pharmaceuticals, Inc., Hollis-Eden Pharmaceuticals, Inc., Nanogen, Inc., Gensia Sicor, Inc., Castle & Cooke, Inc. and Smith Barney, Harris Upham and Company. Mr. Burgess serves as a director of Arbutus Biopharma Corporation and chairman of the board of Nabriva Therapeutics plc, each of which is a publicly-traded pharmaceutical company, as well as a director of several private companies. From July 2004 until its acquisition by Salix Pharmaceuticals, Inc. in January 2014, Mr. Burgess served on the board of directors of Santarus, Inc., a publicly-traded biopharmaceutical company. Mr. Burgess holds a B.A. in economics from Stanford University and an M.B.A. from Harvard Business School.
What is the salary of Daniel Burgess?
As the Independent Chairman of the Board of Cidara Therapeutics Inc, the total compensation of Daniel Burgess at Cidara Therapeutics Inc is $84,159. There are 6 executives at Cidara Therapeutics Inc getting paid more, with Jeffrey Stein having the highest compensation of $1,451,970.
How old is Daniel Burgess?
Daniel Burgess is 58, he's been the Independent Chairman of the Board of Cidara Therapeutics Inc since 2020. There are 6 older and 12 younger executives at Cidara Therapeutics Inc. The oldest executive at Cidara Therapeutics Inc is Dr. Kenneth F. Bartizal Ph.D., 70, who is the Chief Devel. Officer.
What's Daniel Burgess's mailing address?
Daniel's mailing address filed with the SEC is 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO, CA, 92121.
Insiders trading at Cidara Therapeutics Inc
Over the last 15 years, insiders at Cidara Therapeutics Inc have traded over $256,071 worth of Cidara Therapeutics Inc stock and bought 1,216,676 units worth $9,796,257 . The most active insiders traders include Capital Management, L.P.Ra ..., Target N Vbb Biotech Ag Bio..., eSteve Elms. On average, Cidara Therapeutics Inc executives and independent directors trade stock every 52 days with the average trade being worth of $282,598. The most recent stock trade was executed by Jeffrey Stein on 7 June 2024, trading 8,000 units of CDTX stock currently worth $105,680.
What does Cidara Therapeutics Inc do?
cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.
What does Cidara Therapeutics Inc's logo look like?
Complete history of Mr. Burgess stock trades at Arbutus Biopharma Corp, Cidara Therapeutics Inc, eNabriva Therapeutics Plc
Cidara Therapeutics Inc executives and stock owners
Cidara Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Jeffrey Stein,
President, Chief Executive Officer, Director -
Dr. Jeffrey L. Stein Ph.D.,
Pres, CEO & Exec. Director -
Neil Abdollahian,
Chief Business Officer -
Taylor Sandison,
Chief Medical Officer -
Paul Daruwala,
Chief Operating Officer -
Dr. Taylor Sandison,
Chief Medical Officer -
Daniel Burgess,
Independent Chairman of the Board -
Theodore Schroeder,
Independent Director -
Chrysa Mineo,
Independent Director -
Timothy Franson,
Independent Director -
David Gollaher,
Independent Director -
Robert Uhl,
IR Contact Officer -
Jessica Oien,
General Counsel, Secretary -
James Levine,
Chief Financial Officer -
Dr. Kenneth F. Bartizal Ph.D.,
Chief Devel. Officer -
Allison Lewis CCP, SPHR,
VP of HR -
Shane M. Ward,
Chief Legal Officer & Corp. Sec. -
Christopher A. Kurtz,
Exec. VP of Technical Operations -
Brady Johnson,
Principal Accounting Officer, Controller & VP of Fin. -
Paul Daruwala,
COO & Chief Commercial Officer -
Dr. Preetam Shah M.B.A., Ph.D.,
CFO & Chief Bus. Officer -
Dr. Kevin M. Forrest Ph.D.,
Founder and Chief Strategy Officer -
Robert J Perez,
Director -
Scott M Rocklage,
Director -
Ken Bartizal,
Chief Development Officer -
Matthew Onaitis,
Gnrl Counsel, CFO & Secretary -
Marc Wilson,
Chief Accounting Officer -
Dirk Thye,
Chief Medical Officer -
Kevin Forrest,
COO & CFO -
Laura Tadvalkar,
Director -
Preetam Shah,
CFO & CBO -
Target N Vbb Biotech Ag Bio...,
-
Patrick J Heron,
Director -
Nina S Kjellson,
Director -
Steve Elms,
Director -
Bonnie L Bassler,
Director -
Carin Canale Theakston,
Director -
Leslie Tari,
CHIEF SCIENTIFIC OFFICER -
Brady Johnson,
Vice President, Finance -
Shane Ward,
COO & CLO -
Ryan Spencer,
Director -
James Merson,
Director -
Capital Management, L.P.Ra ...,